Dishman Carbogen Amcis’ wholly owned subsidiary -- Carbogen Amcis AG has entered into a co-investment agreement of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.
The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling Carbogen Amcis to meet rising global demand. This project builds on a previous joint funding agreement between Carbogen Amcis and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.
Carbogen Amcis is recognised for its robust capabilities in handling highly potent compounds, offering end-to-end support from process development to commercial supply. The new investments will further strengthen the company’s infrastructure to deliver high-quality manufacturing services in line with cGMP and global regulatory expectations.
Dishman Carbogen Amcis (DCAL), incorporated in 1983, started out as a manufacturer of quaternary ammonium and phosphate compounds. Currently, the company is a fully integrated CRAMS player working with global pharmaceutical innovators.
